



Holista Colltech Limited
(ASX:HCT / ABN 24 094 515 992)
283 Rokeby Road, Subiaco WA 6008
P: +61 412 474 180
W: www.holistaco.com

Tests on Holista's All-Natural Nano Silver Disinfectant Show it Kills 99.99% of Human Coronavirus Strain

ASX Announcement

29 April 2022

Holista Colltech Limited (ASX: HCT, “**Holista**” or “the **Company**”) is pleased to announce the independent test results from SGS (Malaysia) Sdn Bhd (**SGS**) confirming the efficacy of the Company's all-natural Super Bio Nano Silver disinfectant.

The Objective of the Test

The goal of quantitative suspension tests undertaken by SGS was to evaluate the virucidal activity of the Company's innovation against human coronavirus (ATCC VR-740) and the results showed that Super Bio Nano Silver killed 99.99% of the human coronavirus (ATCC VR-740) after 30 and 60 minutes under the stated condition in accordance with approved European standard EN 14476:2013+A2:2019.¹ The standard relates to chemical disinfectants and antiseptics and is a quantitative suspension test for the evaluation of virucidal activity in the medical area.

The Testing Period

The test was carried out in accredited labs of SGS in Malaysia between 15 March 2022 and 31 March 2022.

The Test Organism

The test organism used is Human coronavirus, strain 229E, ATCC VR-740. Human coronavirus 229E is propagated in MRC-5 cells (ATCC CCL-171). This strain was isolated from the nasal and throat swabs of a man with a mild upper respiratory illness. The strain has applications in respiratory disease research and does not result in hemolysis.

The Testing Method

The virucidal activity of the disinfectant Super Bio Nano Silver (Silaeris AgNP) against Human coronavirus ATCC VR-740 was investigated by a quantitative suspension test method according to EN 14476:2013+A2:2019 (E) under clean condition (0.30 g/L Bovine Albumin Solution). According to this suspension test, a disinfectant or a disinfectant solution at a particular concentration is considered as having virucidal activity if the virus titre is reduced by $\geq 4 \log_{10}$ (inactivation $\geq 99.99\%$) within the recommended exposure period.

Super Bio Nano Silver (Silaeris AgNP) was examined at 20°C at the concentration(s) of 150.00ppm for the exposure time(s) of 30 and 60 minutes. After the exposure time(s), the viral reduction exceeded 4 log₁₀-steps in all assays. According to the simple acceptance decision rule†, there is <50% risk of false acceptance. Therefore, a virucidal activity against Human coronavirus ATCC VR-740 was measured as follows:

Clean condition 150.00 ppm 30 minutes

Clean condition 150.00 ppm 60 minutes

The Results

Super Bio Nano Silver (Silaeris AgNP) killed 99.99% of the human coronavirus (ATCC VR-740) where it was examined at 20°C at the concentration(s) of 150.00ppm [parts per million] for the exposure time(s) of 30 and 60 minutes. After the exposure time(s), the viral reduction exceeded 4 log₁₀-steps in all assays.

Holista has been working on this proprietary technology since June 2021.

The expert opinion expressed in the SGS report concluded below and no further testing is required.

A copy of the SGS test report is available at
<https://www.holistaco.com/pdf/products/nano-silver/nano-silver-test-report.pdf>.

This announcement has been approved by the Board of Directors.

-ENDS-

1. Expert Opinion

This expert opinion is based on the test report CPSA/220484116-CA87921 dated 01st April 2022.

The virucidal activity of the disinfectant Super Bio Nano Silver (Silaeris AgNP) of Holista Biotech Sdn Bhd against *Human coronavirus* ATCC VR-740 was investigated by a quantitative suspension test according to EN 14476:2013+A2:2019 (E) under clean condition (0.30 g/L Bovine Albumin Solution).

According to this suspension test, a disinfectant or a disinfectant solution at a particular concentration is considered as having virucidal activity if the virus titre is reduced by ≥ 4 log₁₀ (inactivation $\geq 99.99\%$) within the recommended exposure period.

Super Bio Nano Silver (Silaeris AgNP) was examined at 20°C at the concentration(s) of 150.00ppm for the exposure time(s) of 30 and 60 minutes. After the exposure time(s), the viral reduction exceeded 4 log₁₀-steps in all assays. According to the simple acceptance decision rule†, there is <50% risk of false acceptance. Therefore, a virucidal activity against *Human coronavirus* ATCC VR-740 was measured as follows:

Clean condition 150.00 ppm 30 minutes

Clean condition 150.00 ppm 60 minutes

*Opinions and interpretations expressed here are outside the scope of SAMM (Laboratory Accreditation Scheme of Malaysia) accreditation.

†The decision rule applied is simple acceptance rule with no guard band and up to 50% risk of false acceptance or rejection. This rule has been determined by the laboratory and agreed with the client prior to testing.

About Holista Colltech Limited

Holista Colltech Ltd ("**Holista**" or "**the Company**") is an innovator in health and wellness solutions based in Perth, Western Australia. It is listed on the Australian Securities Exchange (ASX:HCT).

Holista's core business divisions are Dietary Supplements, Healthy Food Ingredients, Ovine Collagen and Infection Control Solutions. The suite of health and food related solutions, combines the best of nature and science to address evolving needs in order that people may live better and healthier lives.

Key products include one of the market-leading and best-selling health supplements, low-GI food ingredients used by leading food manufacturers, disease-free ovine collagen, all-natural and non-toxic effective sanitisers for consumers and industrial applications.

Over the years, the company has successfully developed and patented world-leading technologies in the field of Global Health and Wellness Industry.

Holista is passionate about combining economic success with enriching lives for a sustainable future.

For further information, please contact:

Our Investor Mailing list: investor@holistaco.com

General Enquiries: enquiries@holistaco.com

Australia

283 Rokeby Road Subiaco
WA 6008 Western Australia
Australia
P: +61 412 474 180

Malaysia

12th Floor, Amcorp Trade Centre, PJ
Tower No. 18, Persiaran Barat off Jalan
Timur 46000, Petaling Jaya, Malaysia
P: +603 7965 2828 ; F: +603 7965 2777

Australia and New Zealand Investor relations and media enquiries:

Brendon Lau, Vantage Point Partners
E: brendon@vantagepointpartners.com.au
M: +61 409 341 613

Global Investor relations and media enquiries:

WeR1 Consultants Pte Ltd
E: holista@wer1.net
M: +65 6721 7161